Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

PR Newswire October 11, 2021

Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting

PR Newswire October 4, 2021

PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

Business Wire September 22, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX

Newsfile September 21, 2021

Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program

PR Newswire September 17, 2021

Protagonist Therapeutics Reports Granting of Inducement Awards

PR Newswire September 15, 2021

Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology

PR Newswire September 7, 2021

Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma

PR Newswire August 10, 2021

Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress

PR Newswire August 4, 2021

Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists

PR Newswire July 28, 2021

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire June 30, 2021

Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire June 18, 2021

Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock

PR Newswire June 15, 2021

Protagonist Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire June 14, 2021

Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera

PR Newswire June 11, 2021

Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021

PR Newswire June 7, 2021

Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera

PR Newswire June 3, 2021

Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232

PR Newswire May 24, 2021

Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021

PR Newswire May 12, 2021

Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update

PR Newswire May 4, 2021